Brief: LumiraDx Expands Its Cardiovascular Testing Portfolio
02/06/2022 11:43
June 2 (Reuters) - LumiraDx Ltd LMDX.O :
* LUMIRADX EXPANDS ITS CARDIOVASCULAR TESTING PORTFOLIO WITH
CE
MARKING OF ITS NT-PROBNP TEST AND NEW EXCLUSION CLAIM FOR ITS
D-DIMER TEST
* LUMIRADX LTD - LUMIRADX NT-PROBNP TEST IS EXPECTED TO
BEGIN
COMMERCIALIZATION LATER THIS YEAR
* LUMIRADX LTD - LUMIRADX D-DIMER TEST IS COMMERCIALLY
AVAILABLE
ACROSS EUROPE
Source text for Eikon: ID:nPn5n56Ysa
Further company coverage: LMDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LumiraDx
See all newsBrief: LumiraDx Announces Its Securities Will Be Suspended From Trading On Nasdaq At The Open Of Business On January 9Th
Roche to buy part of LumiraDx diagnostics platform for $295 million
Brief: LumiraDx- Under Terms Of Certain Loan Agreement, Dated March 23, 2021, The Waiver Period Has Expired As Of Today
Brief: LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
Brief: Willard L. Umphrey Reports 10.31% Stake In Lumiradx Limited As Of Dec 22- SEC Filing